Development status of miltefosine as first oral drug in visceral and cutaneous leishmaniasis View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2001-11

AUTHORS

C. Fischer, A. Voss, J. Engel

ABSTRACT

An oral treatment for visceral and cutaneous leishmaniasis has been searched for over the last decades. An oral drug would facilitate treatment and lower costs. Oral miltefosine (Zentaris/ASTA Medica AG, Germany), an alkylphosphocholine, is under clinical development for treatment of leishmaniasis. Phase I, II and III clinical trials have been performed in visceral leishmaniasis in India; the overall response rate with 100 mg/day over 4 weeks is 96%. A first clinical trial in New World cutaneous leishmaniasis has shown a final cure rate of 94% at a dose of 150 mg/day over 3 or 4 weeks. Side effects are mainly gastrointestinal (vomiting, diarrhoea). Furthermore, transient elevation of transaminases or urea/creatinine has been observed. The clinical results suggest that miltefosine is the first oral therapy that is effective and safe in visceral and cutaneous leishmaniasis. More... »

PAGES

85-87

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s004300100087

DOI

http://dx.doi.org/10.1007/s004300100087

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1038394358

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/11770118


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antiprotozoal Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child, Preschool", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Industry", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leishmaniasis, Cutaneous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leishmaniasis, Visceral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phosphorylcholine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "World Health Organization", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Zentaris/ASTA Medica AG, Frankfurt am Main, Germany, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fischer", 
        "givenName": "C.", 
        "id": "sg:person.01245553000.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01245553000.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bayer (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.420044.6", 
          "name": [
            "Present address: Anti-Infectives/Oncology, Bayer Vital GmbH, Leverkusen, Germany, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Voss", 
        "givenName": "A.", 
        "id": "sg:person.01057000510.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01057000510.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Zentaris/ASTA Medica AG, Frankfurt am Main, Germany, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Engel", 
        "givenName": "J.", 
        "id": "sg:person.015106662512.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015106662512.93"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/978-1-4899-0179-8_33", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002936283", 
          "https://doi.org/10.1007/978-1-4899-0179-8_33"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(98)04367-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011428740"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/aac.36.8.1630", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014757281"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm199912093412403", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030500795"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-199856060-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033911128", 
          "https://doi.org/10.2165/00003495-199856060-00005"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0006-2952(87)90543-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052965645"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0006-2952(87)90543-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052965645"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/00034983.1999.11813462", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1058266085"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2001-11", 
    "datePublishedReg": "2001-11-01", 
    "description": "An oral treatment for visceral and cutaneous leishmaniasis has been searched for over the last decades. An oral drug would facilitate treatment and lower costs. Oral miltefosine (Zentaris/ASTA Medica AG, Germany), an alkylphosphocholine, is under clinical development for treatment of leishmaniasis. Phase I, II and III clinical trials have been performed in visceral leishmaniasis in India; the overall response rate with 100 mg/day over 4 weeks is 96%. A first clinical trial in New World cutaneous leishmaniasis has shown a final cure rate of 94% at a dose of 150 mg/day over 3 or 4 weeks. Side effects are mainly gastrointestinal (vomiting, diarrhoea). Furthermore, transient elevation of transaminases or urea/creatinine has been observed. The clinical results suggest that miltefosine is the first oral therapy that is effective and safe in visceral and cutaneous leishmaniasis.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s004300100087", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1014962", 
        "issn": [
          "0300-8584", 
          "1432-1831"
        ], 
        "name": "Medical Microbiology and Immunology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1-2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "190"
      }
    ], 
    "name": "Development status of miltefosine as first oral drug in visceral and cutaneous leishmaniasis", 
    "pagination": "85-87", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "b6e5197b47599918cefff8ca258677832f0104abea029bb424b9a845837d2874"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "11770118"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "0314524"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s004300100087"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1038394358"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s004300100087", 
      "https://app.dimensions.ai/details/publication/pub.1038394358"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T01:07", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8697_00000514.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs004300100087"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s004300100087'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s004300100087'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s004300100087'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s004300100087'


 

This table displays all metadata directly associated to this object as RDF triples.

162 TRIPLES      21 PREDICATES      49 URIs      34 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s004300100087 schema:about N0d652caafc1b48bc8fa85076eb2adf21
2 N0f05a6f78f404faca371152e82f5637e
3 N1510a1e8b5d04cc98bd8bcee024fcbdc
4 N201b93019c6d4032a40c08a771c7825b
5 N23b6616f9fda49d8b986b53faf8f8985
6 N292b5490875e4d87ab414f1dd71338e9
7 N4bd10d30652243018f2a3c4b5184c8b5
8 N5ad862d4e3ec43749bca013bd2ba177e
9 N81a397a641e7407d806503a7bc7ed060
10 Na5f3b9b4253d4c72934d8df1b9ee38f8
11 Na65d8fae51f248029bfd95541fa8c73d
12 Na9fbc9cae9c34d32a27bd3c45085a624
13 Nf57b45e4e83a475883735ae0e8589386
14 anzsrc-for:11
15 anzsrc-for:1103
16 schema:author N2a6c1c8dc85849dd8055d0b904239050
17 schema:citation sg:pub.10.1007/978-1-4899-0179-8_33
18 sg:pub.10.2165/00003495-199856060-00005
19 https://doi.org/10.1016/0006-2952(87)90543-0
20 https://doi.org/10.1016/s0140-6736(98)04367-0
21 https://doi.org/10.1056/nejm199912093412403
22 https://doi.org/10.1080/00034983.1999.11813462
23 https://doi.org/10.1128/aac.36.8.1630
24 schema:datePublished 2001-11
25 schema:datePublishedReg 2001-11-01
26 schema:description An oral treatment for visceral and cutaneous leishmaniasis has been searched for over the last decades. An oral drug would facilitate treatment and lower costs. Oral miltefosine (Zentaris/ASTA Medica AG, Germany), an alkylphosphocholine, is under clinical development for treatment of leishmaniasis. Phase I, II and III clinical trials have been performed in visceral leishmaniasis in India; the overall response rate with 100 mg/day over 4 weeks is 96%. A first clinical trial in New World cutaneous leishmaniasis has shown a final cure rate of 94% at a dose of 150 mg/day over 3 or 4 weeks. Side effects are mainly gastrointestinal (vomiting, diarrhoea). Furthermore, transient elevation of transaminases or urea/creatinine has been observed. The clinical results suggest that miltefosine is the first oral therapy that is effective and safe in visceral and cutaneous leishmaniasis.
27 schema:genre research_article
28 schema:inLanguage en
29 schema:isAccessibleForFree false
30 schema:isPartOf N3de72896d1a545d19ed3695f3da36f95
31 N63bc58749e944b0d82214f01fcb18734
32 sg:journal.1014962
33 schema:name Development status of miltefosine as first oral drug in visceral and cutaneous leishmaniasis
34 schema:pagination 85-87
35 schema:productId N0f7f8501046a45139b133647cea0c62f
36 N4d96c7a03f8b46cc9d4ff692a333f236
37 Na8f03f82f88d4d6c8fe061a0f258368b
38 Nd2de0e08ed30475598bbd179c842c8fb
39 Nee354ba41d104f509b7f62a3aa79338d
40 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038394358
41 https://doi.org/10.1007/s004300100087
42 schema:sdDatePublished 2019-04-11T01:07
43 schema:sdLicense https://scigraph.springernature.com/explorer/license/
44 schema:sdPublisher N8c175f98761746de9ad18c1a131e0412
45 schema:url http://link.springer.com/10.1007%2Fs004300100087
46 sgo:license sg:explorer/license/
47 sgo:sdDataset articles
48 rdf:type schema:ScholarlyArticle
49 N0d652caafc1b48bc8fa85076eb2adf21 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
50 schema:name Child, Preschool
51 rdf:type schema:DefinedTerm
52 N0f05a6f78f404faca371152e82f5637e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
53 schema:name Humans
54 rdf:type schema:DefinedTerm
55 N0f7f8501046a45139b133647cea0c62f schema:name doi
56 schema:value 10.1007/s004300100087
57 rdf:type schema:PropertyValue
58 N1510a1e8b5d04cc98bd8bcee024fcbdc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
59 schema:name Administration, Oral
60 rdf:type schema:DefinedTerm
61 N201b93019c6d4032a40c08a771c7825b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
62 schema:name Leishmaniasis, Visceral
63 rdf:type schema:DefinedTerm
64 N23b6616f9fda49d8b986b53faf8f8985 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
65 schema:name Leishmaniasis, Cutaneous
66 rdf:type schema:DefinedTerm
67 N292b5490875e4d87ab414f1dd71338e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
68 schema:name Antiprotozoal Agents
69 rdf:type schema:DefinedTerm
70 N2a6c1c8dc85849dd8055d0b904239050 rdf:first sg:person.01245553000.35
71 rdf:rest Nf483038814834bc49b261e2a1413c420
72 N3884653b35a047c3863051306b091399 schema:name Zentaris/ASTA Medica AG, Frankfurt am Main, Germany, Germany
73 rdf:type schema:Organization
74 N3de72896d1a545d19ed3695f3da36f95 schema:issueNumber 1-2
75 rdf:type schema:PublicationIssue
76 N4bd10d30652243018f2a3c4b5184c8b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Drug Industry
78 rdf:type schema:DefinedTerm
79 N4d96c7a03f8b46cc9d4ff692a333f236 schema:name pubmed_id
80 schema:value 11770118
81 rdf:type schema:PropertyValue
82 N5ad862d4e3ec43749bca013bd2ba177e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Phosphorylcholine
84 rdf:type schema:DefinedTerm
85 N63bc58749e944b0d82214f01fcb18734 schema:volumeNumber 190
86 rdf:type schema:PublicationVolume
87 N81a397a641e7407d806503a7bc7ed060 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name World Health Organization
89 rdf:type schema:DefinedTerm
90 N8c175f98761746de9ad18c1a131e0412 schema:name Springer Nature - SN SciGraph project
91 rdf:type schema:Organization
92 Na5f3b9b4253d4c72934d8df1b9ee38f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Clinical Trials as Topic
94 rdf:type schema:DefinedTerm
95 Na65d8fae51f248029bfd95541fa8c73d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Drug Administration Schedule
97 rdf:type schema:DefinedTerm
98 Na8f03f82f88d4d6c8fe061a0f258368b schema:name nlm_unique_id
99 schema:value 0314524
100 rdf:type schema:PropertyValue
101 Na9fbc9cae9c34d32a27bd3c45085a624 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Child
103 rdf:type schema:DefinedTerm
104 Nc05b95f1cbb14195bd139b6a2e2462c0 schema:name Zentaris/ASTA Medica AG, Frankfurt am Main, Germany, Germany
105 rdf:type schema:Organization
106 Nd2de0e08ed30475598bbd179c842c8fb schema:name dimensions_id
107 schema:value pub.1038394358
108 rdf:type schema:PropertyValue
109 Nebadd83ff5a54c7f827780e3b5cef2ab rdf:first sg:person.015106662512.93
110 rdf:rest rdf:nil
111 Nee354ba41d104f509b7f62a3aa79338d schema:name readcube_id
112 schema:value b6e5197b47599918cefff8ca258677832f0104abea029bb424b9a845837d2874
113 rdf:type schema:PropertyValue
114 Nf483038814834bc49b261e2a1413c420 rdf:first sg:person.01057000510.76
115 rdf:rest Nebadd83ff5a54c7f827780e3b5cef2ab
116 Nf57b45e4e83a475883735ae0e8589386 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Adult
118 rdf:type schema:DefinedTerm
119 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
120 schema:name Medical and Health Sciences
121 rdf:type schema:DefinedTerm
122 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
123 schema:name Clinical Sciences
124 rdf:type schema:DefinedTerm
125 sg:journal.1014962 schema:issn 0300-8584
126 1432-1831
127 schema:name Medical Microbiology and Immunology
128 rdf:type schema:Periodical
129 sg:person.01057000510.76 schema:affiliation https://www.grid.ac/institutes/grid.420044.6
130 schema:familyName Voss
131 schema:givenName A.
132 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01057000510.76
133 rdf:type schema:Person
134 sg:person.01245553000.35 schema:affiliation N3884653b35a047c3863051306b091399
135 schema:familyName Fischer
136 schema:givenName C.
137 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01245553000.35
138 rdf:type schema:Person
139 sg:person.015106662512.93 schema:affiliation Nc05b95f1cbb14195bd139b6a2e2462c0
140 schema:familyName Engel
141 schema:givenName J.
142 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015106662512.93
143 rdf:type schema:Person
144 sg:pub.10.1007/978-1-4899-0179-8_33 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002936283
145 https://doi.org/10.1007/978-1-4899-0179-8_33
146 rdf:type schema:CreativeWork
147 sg:pub.10.2165/00003495-199856060-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033911128
148 https://doi.org/10.2165/00003495-199856060-00005
149 rdf:type schema:CreativeWork
150 https://doi.org/10.1016/0006-2952(87)90543-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052965645
151 rdf:type schema:CreativeWork
152 https://doi.org/10.1016/s0140-6736(98)04367-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011428740
153 rdf:type schema:CreativeWork
154 https://doi.org/10.1056/nejm199912093412403 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030500795
155 rdf:type schema:CreativeWork
156 https://doi.org/10.1080/00034983.1999.11813462 schema:sameAs https://app.dimensions.ai/details/publication/pub.1058266085
157 rdf:type schema:CreativeWork
158 https://doi.org/10.1128/aac.36.8.1630 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014757281
159 rdf:type schema:CreativeWork
160 https://www.grid.ac/institutes/grid.420044.6 schema:alternateName Bayer (Germany)
161 schema:name Present address: Anti-Infectives/Oncology, Bayer Vital GmbH, Leverkusen, Germany, Germany
162 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...